Orexo AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORX.ST research report →
Companywww.orexo.com
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain.
- CEO
- Nikolaj Sorensen
- IPO
- 2005
- Employees
- 110
- HQ
- Uppsala, SE
Price Chart
Valuation
- Market Cap
- $699.72M
- P/E
- -2.82
- P/S
- 2.85
- P/B
- 1.92
- EV/EBITDA
- -0.90
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -75.57%
- Op Margin
- -94.37%
- Net Margin
- -101.06%
- ROE
- -228.39%
- ROIC
- -60.99%
Growth & Income
- Revenue
- $26.00M · -95.59%
- Net Income
- $-129,800,000 · 36.06%
- EPS
- $-3.75 · 36.33%
- Op Income
- $-346,900,000
- FCF YoY
- 565.05%
Performance & Tape
- 52W High
- $43.40
- 52W Low
- $14.38
- 50D MA
- $20.66
- 200D MA
- $26.38
- Beta
- 0.87
- Avg Volume
- 46.40K
Get TickerSpark's AI analysis on ORX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ORX.ST Coverage
We haven't published any research on ORX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ORX.ST Report →